- Trials with a EudraCT protocol (339)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
339 result(s) found for: T lymphocytes.
Displaying page 1 of 17.
EudraCT Number: 2012-002418-38 | Sponsor Protocol Number: LUMC2012-01 | Start Date*: 2012-08-21 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor | |||||||||||||
Medical condition: Patients with AML, MDS, ALL, CML in accelerated phase or blastic transformation, CLL, MM or aggressive lymphoma, who underwent a (non) myeloablative allo-SCT with an unrelated donor. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000417-16 | Sponsor Protocol Number: Uni-Köln-4480 | Start Date*: 2021-10-20 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 | |||||||||||||
Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001447-19 | Sponsor Protocol Number: LUMCCD4PROTOCOL | Start Date*: 2008-05-27 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted stem cell transplantation | ||
Medical condition: Patients with AML, myelodysplasia (MDS), ALL, CML in accelerated phase or blastic transformation, CLL, MM or aggressive lymphoma, who underwent allo SCT (both myeloablative and non-myeloablative). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001749-38 | Sponsor Protocol Number: IL2-COVID | Start Date*: 2020-10-02 |
Sponsor Name:Azienda Ospedaliero-Universitaria S. Andrea | ||
Full Title: PET/CT with 68Ga-IL2 for imaging IL2R+ cells in COVID-19+ patients | ||
Medical condition: Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005582-13 | Sponsor Protocol Number: CHUBX2020/26 | Start Date*: 2021-03-03 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Prospective pilot study evaluating a therapeutic synergy between the infusion of CMV-specific immunoglobulins and the level before transplantation of negative gamma delta Vdelta 2 T lymphocytes exp... | ||
Medical condition: CMV infection in transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006146-34 | Sponsor Protocol Number: 100505 | Start Date*: 2008-04-30 |
Sponsor Name:Stage Pharmaceuticals GmbH | ||
Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial | ||
Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005150-28 | Sponsor Protocol Number: PTC:VS-TC | Start Date*: 2022-07-25 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT) | |||||||||||||
Medical condition: Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003270-32 | Sponsor Protocol Number: IISR-2014-100922 | Start Date*: 2016-02-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Identification of circulating and tissutal T cell subsets to predict clinical and endoscopical response to Entyvio® (vedolizumab) in patients with Ulcerative Colitis (UC) and Crohn’s disease (CD) | |||||||||||||
Medical condition: Ulcerative colitis (UC) and Crohn disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000433-30 | Sponsor Protocol Number: UCL/17/0053 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma | |||||||||||||
Medical condition: Cutaneous T cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001827-76 | Sponsor Protocol Number: 1983 | Start Date*: 2009-11-26 | |||||||||||
Sponsor Name:Erasmusm MC, Rotterdam, The Netherlands | |||||||||||||
Full Title: The role of TSH in the human immune system, a clinical trial | |||||||||||||
Medical condition: All conditions in which a T cell immunodeficiency is present. Examples are genetic immunodeficiencies, chronic viral infections like HIV, after chemotherapy or bone marrow transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004331-39 | Sponsor Protocol Number: INDOOR | Start Date*: 2015-01-02 | |||||||||||
Sponsor Name:Fundació Vall Hebron Institut de Recerca | |||||||||||||
Full Title: HIV Reservoir Dynamics After Switching To Dolutegravir in Patients on a PI/r Based Regimen. A Phase IV Open Randomized Trial | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001263-70 | Sponsor Protocol Number: IIBSP-CAR-2019-30 | Start Date*: 2020-03-03 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 sp... | ||
Medical condition: Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003997-74 | Sponsor Protocol Number: 2005-1 | Start Date*: 2006-02-09 |
Sponsor Name:Rigshospitalet | ||
Full Title: Depletion of regulatory T-lymphocytes by intratumoral injection of antibodies. | ||
Medical condition: Cancer with metastasis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004380-31 | Sponsor Protocol Number: CM-2013-01 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Cell Medica Inc. | |||||||||||||
Full Title: A Phase 2 open label study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive extranodal NK/T-cell lymphoma (ENKTCL). | |||||||||||||
Medical condition: Aggressive EBV positive extranodal NK/T-cell lymphoma (ENKTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000881-39 | Sponsor Protocol Number: P/2019/418 | Start Date*: 2019-12-10 |
Sponsor Name:CHU de Besançon | ||
Full Title: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers | ||
Medical condition: cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000054-63 | Sponsor Protocol Number: HNJ-NKAES-2012 | Start Date*: 2012-07-25 |
Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS | ||
Full Title: Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma. | ||
Medical condition: Relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006126-10 | Sponsor Protocol Number: Efalizumab in CTCL | Start Date*: 2008-11-27 |
Sponsor Name:Charité - University Hospital Berlin | ||
Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma | ||
Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-004885-24 | Sponsor Protocol Number: ANRS 141 | Start Date*: 2009-01-19 | |||||||||||
Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS. | |||||||||||||
Full Title: Essai pilote multicentrique évaluant la capacité d’une stratégie de traitement antirétroviral intermittent à maintenir une stabilité immunologique chez des patients infectés par le VIH-1, jamais tr... | |||||||||||||
Medical condition: Infection VIH | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003409-23 | Sponsor Protocol Number: MERMAID1 | Start Date*: 2023-12-12 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I... | |||||||||||||
Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022293-14 | Sponsor Protocol Number: ANRS146OPTIMAL | Start Date*: 2012-08-22 |
Sponsor Name:Inserm-ANRS | ||
Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
